Mycapssa (Octreotide Acetate) Patent Expiration, LOE Window & CMS Spending

Mycapssa (Octreotide Acetate) by Chiesi Farmaceutici Spa: FDA Orange Book LOE 2040-12-28, 2 AB generics, $12.2M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorChiesi Farmaceutici Spa
FDA Application & PathwayN208232 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-12-28
Orange Book Patents (*PED Extensions)16 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$12.2M
2024 Medicare Part D Spend$9.6M
2024 Medicaid Spend$2.6M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 15.5% 2-yr change)